FDA Approves Durvalumab for Relapsed/Refractory Urothelial Carcinoma

Share this content:
The US Food and Drug Administration has approved durvalumab — a PD-L1 inhibitor — for the treatment of locally advanced or metastatic urothelial carcinoma.
The US Food and Drug Administration has approved durvalumab — a PD-L1 inhibitor — for the treatment of locally advanced or metastatic urothelial carcinoma.

The US Food and Drug Administration (FDA) has approved durvalumab — a PD-L1 inhibitor — for the treatment of locally advanced or metastatic urothelial carcinoma among patients whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.1

The companion diagnostic, the VENTANA PD-L1 (SP263) Assay, was also approved for the evaluation of PD-L1 protein expression of urothelial carcinoma tissue.

Durvalumab is recommended every 2 weeks at a 10 mg/kg intravenous infusion over 60 min until disease progression or unacceptable toxicity.

Durvalumab was approved based on a single-arm trial of 182 patients, in which the confirmed objective response (ORR) rate by independent central review was 17% (95% CI, 11.9-23.3%).

In the study, the ORR was highest among patients with higher PD-L1 expression levels. The ORR was 26.3% (95% CI, 17.8-36.4) among patients with a high score and 4.1% (95% CI, 0.9-11.5) among patients with a low or negative score.

The median duration of response was not reached at data cutoff and had a range of 0.9+ to 19.9+ months.

RELATED: FDA Grants Priority Review to Avelumab for Urothelial Carcinoma

The FDA granted durvalumab an accelerated approval after being granted Breakthrough Therapy Designation and is contingent on confirmation of clinical benefit from an ongoing clinical trial.

Prescribing information can be found here.

Reference

  1. Durvalumab (Imfinzi) [news release]. Silver Spring, MD: US Food and Drug Administration; May 1, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm. Accessed May 1, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters